Corporate News     16-Oct-24
OneSource Specialty Pharma receives pre-money equity valuation of USD 1.65 bn
Receives confirmed equity commitments of Rs 801 cr from marquee investors

Strides Pharma Science (Strides) today announced that its associate company, OneSource Specialty Pharma (formerly known as Stelis Biopharma), Group's Specialty Pharma CDMO, has received confirmed commitments for fundraising of Rs 801 crore (~USD 95 mn) from marquee domestic and foreign institutional investors and family offices, in the pre-listing round.

The share subscription agreements are being executed at a pre-money equity value of USD 1.65 bn, delivering to Strides' shareholders an embedded value of Rs 663 per share of Strides' holding in OneSource representing an ~82% premium over the previous embedded value of Rs 364 per share as per the Scheme of Arrangement announced earlier in September'23. The strong interest from leading investors reflects growing confidence in our capabilities and the immense potential of the CDMO sector emerging out of India. This fundraise is in line with the Scheme of Arrangement announced in September'23.

Arun Kumar, Founder of Strides Group, and Neeraj Sharma, CEO of OneSource in a statement said, "We are delighted to have received an overwhelming response to the pre-listing fundraise from a marquee set of investors on our cap table prior to our listing. Their strong support is a testament to the confidence they have in our vision and strategic direction. This fundraise will enable us to accelerate our growth plans, right-size our debt book, and commit significant new capex for a strong order book across our 3 platforms.”

Background: On 25 September 2023, Strides announced the creation of OneSource, India's first specialty pharma pure-play CDMO player by integrating Stelis' Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatine businesses in a single entity by way of Scheme of Arrangement.

Previous News
  Strides Pharma Global, Singapore to acquire balance 30% stake in Strides Switzerland
 ( Corporate News - 25-Oct-24   19:12 )
  Strides Pharma Science reports consolidated net profit of Rs 93.23 crore in the September 2024 quarter
 ( Results - Announcements 24-Oct-24   15:37 )
  Strides Pharma reports turnaround Q2 numbers
 ( Hot Pursuit - 24-Oct-24   14:48 )
  Strides Pharma Science to declare Quarterly Result
 ( Corporate News - 19-Oct-24   10:05 )
  Sensex slides 318 pts; Nifty ends below 25,000; auto shares underpressure
 ( Market Commentary - Quick Review 16-Oct-24   15:48 )
  Barometers trim losses; pharma shares slip
 ( Market Commentary - Mid-Session 16-Oct-24   14:32 )
  Strides Pharma hits record high after arm gets Rs 801 cr fund commitments
 ( Hot Pursuit - 16-Oct-24   11:41 )
  OneSource Specialty Pharma receives pre-money equity valuation of USD 1.65 bn
 ( Corporate News - 16-Oct-24   09:44 )
  Strides Pharma hits record high after arm gets USFDA nod for antidepressant drug
 ( Hot Pursuit - 16-Sep-24   15:53 )
  Strides receives USFDA approval for Fluoxetine Tabs 60 mg
 ( Corporate News - 16-Sep-24   15:22 )
  Strides secures approval of shareholders and creditors for creation of OneSource
 ( Corporate News - 11-Sep-24   14:48 )
Other Stories
  CAMS and KFin Technologies form JV for MF Central
  11-Nov-24   19:02
  L&T Technology Services signs definitive agreements to acquire Intelliswift
  11-Nov-24   19:00
  Balmer Lawrie announces its foray into rail logistics
  11-Nov-24   18:55
  ICRA announces cessation of directors
  11-Nov-24   18:52
  Board of Goodyear India approves change in chairperson
  11-Nov-24   18:50
  Harsha Engineers International appoints director
  11-Nov-24   18:49
  Britannia Industries approves appointment of Jehangir Nusli Wadia on Board
  11-Nov-24   18:46
  Board of EPL approves change in directorate
  11-Nov-24   18:44
  Shree Digvijay Cement Co. allots 4.07 lakh equity shares under ESOP
  11-Nov-24   18:42
  Shriram Finance allots 24,197 equity shares under ESOS
  11-Nov-24   18:41
Back Top